You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Antibody Secreting Cells (ASC) in Human Clostridium Difficile Infection, Colonization, and Reoccurrence

    SBC: MICROBPLEX, INC.            Topic: N/A

    Clostridium difficile infection (CDI) is a common nosocomial pathogen that plagues patients because of it relatively high rate of recurrence. Although diagnosis for primary CDI is very sensitive, there are not tests to predict recurrence. Recent human clinical trials show monocolonal antibodies to toxin A & B are protective for recurrent disease and some natural history studies suggest generation ...

    SBIR Phase I 2014 Department of Health and Human ServicesCenters for Disease Control and Prevention
  2. Development of Novel Targeted Therapy for Prostate Cancer

    SBC: Sophia Bioscience Inc            Topic: NCI

    DESCRIPTION (provided by applicant): Prostate cancer (PCa) is the most diagnosed cancer among men in developed countries including the United States with significant medical cost burdens. Tremendous advances have been made in PCa screening technologies, which allow early detection and treatment. Common treatment options include radical prostatectomy, external beam radiation therapy (RT) and inters ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. VLR-CART Cancer Immunotherapy

    SBC: Novab, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): The mission of Novab is to utilize the unique properties of lamprey generated Variable Lymphocyte Receptors (VLRs) to develop effective, complementary and/or superior therapeutics to those currently derived from mammalian monoclonal antibodies (mMAbs). In the current application, we seek to initiate and demonstrate proof of concept for one commercial project w ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Improving Articulatory Precision in Neurologically Compromised Adults Using Audio

    SBC: Bionic Sciences Inc.            Topic: NIDCD

    DESCRIPTION (provided by applicant): Improving Articulatory Precision in Neurologically Compromised Adults Using Audiovisual Biofeedback. One of the most frustrating impairments of neurological damage is the inability to communicate properly via the speechmodality due to weakness in the oral motor structures, also known as dysarthria. We propose to develop a Tongue Tracking System (TTS) that can p ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Calcaftor, a CFTR stabilizer for Cystic Fibrosis treatment

    SBC: CALISTA THERAPEUTICS INC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Calista Therapeutics has invented Calcaftor, a first-in-class peptide drug that can treat all Cystic Fibrosis (CF) patients. Calcaftor is validated in the gold standard pre-clinical model of CF using F508 -CFTR lung tissue harvested from CF transplant patients. Results from this model demonstrated a gt25 hour duration of action that enables once daily inhaled n ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. On-chip OCT for Ophthalmology applications

    SBC: Sinoora Inc.            Topic: NIBIB

    DESCRIPTION (provided by applicant): Sinoora Inc. proposes to develop an on-chip spectral domain-optical coherence tomography (SD-OCT) system for ophthalmic applications. Phase I will concentrate on demonstrating the passive optical components of the OCT system on a single chip. The passive components include a spectrometer, coupler and an interferometer. These on- chip components will then be int ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Antibodies to O-GlcNAc modified histones for chromatin biology and epigenetic res

    SBC: GLYCOSCIENTIFIC, L.L.C.            Topic: NIGMS

    DESCRIPTION (provided by applicant): O-glycosylation of nuclear and cytoplasmic proteins by a single ?-N-acetyl-D-glucosamine moiety (O-GlcNAc) is a common post-translational modification that is highly dynamic and fluctuates in response to cellular stimuli. This type of glycosylation has been found on approximately a thousand human proteins to date, and is thought to be nearly as wide-spread and ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Cost-effective and high-throughput chromosomal haplotyping

    SBC: 4DGENOME, INC.            Topic: NHGRI

    DESCRIPTION (provided by applicant): Haplotype is fundamental genetic information; it provides essential information for deciphering the functional and etiological roles of genetic variants. Current sequencing and genotyping technologies deliver only halfof the genetic information of each individual. They cannot deliver the other half of the information; the structural conformations of alleles or ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Therapeutic Approach to Hypercholesterolemia Using Next-Generation DNA Sequ

    SBC: ABEOME CORPORATION            Topic: NHLBI

    DESCRIPTION (provided by applicant): We have developed and completed a proof-of-principle on a new transgenic mouse model for comprehensive characterization of the antibody repertoire made in response to ovalbumin injection using surface antibody capture and next-generation DNA sequencing technologies. A more commercially valuable proof is now sought using a novel screening method with an emerging ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Myocardial blood flow quantitation with the novel F-18 Flurpiridaz PET imaging tr

    SBC: SYNTERMED INCORPORATED            Topic: NHLBI

    Coronary artery disease continues to be a major contributor to the cause of death in the United States. The ability to diagnosis CAD in patients at an early stage has improved over the years resulting in reducing the mortality rate. In nuclear medicine/cardiology, the SPECT and PET myocardial perfusion imaging (MPI) methods and radiopharmaceuticals used clinically over the past 10 years have offer ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government